Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1
Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed...
Main Authors: | Kanagasabai Vadivel, Anne K. Zaiss, Yogesh Kumar, Frank M. Fabian, Ayman E. A. Ismail, Mark A. Arbing, Wallace G. Buchholz, William H. Velander, S. Paul Bajaj |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/11/3684 |
Similar Items
-
Plasmin, Immunity, and Surgical Site Infection
by: Stuart Hastings, et al.
Published: (2021-05-01) -
Synthesis and Hemostatic Activity of New Amide Derivatives
by: Banach, L., et al.
Published: (2022) -
Synthesis and Hemostatic Activity of New Amide Derivatives
by: Banach, L., et al.
Published: (2022) -
A comparison of high-dose and low-dose tranexamic acid antifibrinolytic protocols for primary coronary artery bypass surgery
by: Stephen M McHugh, et al.
Published: (2016-01-01) -
Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor
by: Ton Lisman, et al.
Published: (2021-07-01)